Hsp 70/Hsp 90 organizing protein as a nitrosylation target in cystic fibrosis therapy by Nadzeya V. Marozkina et al.
Hsp 70/Hsp 90 organizing protein as a nitrosylation
target in cystic ﬁbrosis therapy
Nadzeya V. Marozkinaa, Sean Yemena, Molly Borowitza, Lei Liub, Melissa Plappa, Fei Sunc, Raﬁque Islamd,
Petra Erdmann-Gilmoree, R. Reid Townsende, Cheryl F. Lichtie, Sneha Mantria, Phillip W. Clappf, Scott H. Randellf,
Benjamin Gastona,1, and Khalequz Zamana,1,2
aDepartment of Pediatric Respiratory Medicine and bDepartment of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA
22908; cDepartment of Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261; dDepartment of Biochemistry and
Biophysics, Texas A&M University, College Station, TX 77843; eWashington University Proteomics Center, St. Louis, MO 63108-2259; and fDepartment of
Medicine, University of North Carolina, Chapel Hill, NC 27599
Edited by Jonathan S. Stamler, Case Western Reserve University, Cleveland, OH, and accepted by the Editorial Board May 4, 2010 (received for review August
12, 2009)
The endogenous signaling molecule S-nitrosoglutathione (GSNO)
and other S-nitrosylating agents can cause full maturation of the
abnormal gene product ΔF508 cystic ﬁbrosis (CF) transmembrane
conductance regulator (CFTR). However, the molecular mechanism
of action is not known. Here we show that Hsp70/Hsp90 organiz-
ing protein (Hop) is a critical target of GSNO, and its S-nitrosylation
results in ΔF508 CFTR maturation and cell surface expression.
S-nitrosylation by GSNO inhibited the association of Hop with
CFTR in the endoplasmic reticulum. This effect was necessary
and sufﬁcient to mediate GSNO-induced cell-surface expression
of ΔF508 CFTR. Hop knockdown using siRNA recapitulated the ef-
fect of GSNO onΔF508 CFTR maturation and expression. Moreover,
GSNO acted additively with decreased temperature, which pro-
moted mutant CFTR maturation through a Hop-independent mech-
anism. We conclude that GSNO corrects ΔF508 CFTR trafﬁcking
by inhibiting Hop expression, and that combination therapies—
using differing mechanisms of action—may have additive beneﬁts
in treating CF.
cystic ﬁbrosis transmembrane conductance regulator | S-nitrosoglutathione
corrector | treatment
The most common mutation associated with cystic ﬁbrosis (CF)results in loss of a single phenylalanine (ΔF508) in the CF
transmembrane conductance regulator (CFTR) apical membrane
chloride channel (1, 2). Posttranslational processing of CFTR re-
quires interactions with chaperones and cochaperones that fold,
glycosylate, and screen the protein for defects (1–3). ΔF508 results
in a misfolding of this CFTR protein, leading to its degradation.
Most wild-type (WT) CFTR—and virtually all ΔF508 CFTR—is
degraded before reaching the cell surface; absence of cell-surface
ΔF508 CFTR after degradation results in abnormal Cl− conduc-
tance in the lung and other organs. Although there is species var-
iation (1–4), CFTR deﬁciency-associated lung disease is commonly
fatal in humans (2). However, ifΔF508 CFTR can be expressed on
the cell surface, it has the potential to be functional (1–3, 5, 6).
Therefore, there is an interest in developing compounds that cor-
rect ΔF508 CFTR to the cell surface as CF treatments (1, 2, 5–7).
S-nitrosoglutathione (GSNO) is an endogenous signaling
molecule that relaxes airway smooth muscle (8–10), enhances
ventilation-perfusion matching (9, 10), increases ciliary beat
frequency (11), has antimicrobial effects (12, 13), and is one of
a class of S-nitrosylating agents that increase expression, matu-
ration, and function of wild-type (WT) and ΔF508 CFTR in
primary nasal and monolayer cultures of epithelial cells (7, 14–
19). The GSNO effect on CFTR is partly transcriptional (16),
but is primarily posttranscriptional (17, 18). Concentration is
critical: levels 10- to 100-fold higher than those normally present
in airway lining ﬂuid can (i) inhibit CFTR transcription (16); (ii)
cause CFTR degradation through tyrosine nitration (20); and
(iii) inhibit WT CFTR function through oxidation (21). How-
ever, lower concentrations of GSNO and other S-nitrosylating
agents augment ΔF508 CFTR expression and maturation. This
effect is independent of NO radical or glutathione generation,
suggesting that the mechanism of action involves transnitrosation
chemistry (10, 18).
We have studied potential transnitrosation targets in the CFTR
interactome (3, 22) of relevance to CFTR trafﬁcking. Here, we
report that GSNO S-nitrosylates heat shock protein (Hsp)70/
Hsp90 organizing protein (Hop)—also known as stress-induced
phosphoprotein 1 (Stip-1) (23)—decreasing Hop expression and de-
creasing the association between Hop and maturing CFTR. This
is essential for the effect of GSNO on ΔF508 CFTR correction,
but it is independent of—and additive with—the effect of de-
creased temperature to correct CFTR. Strikingly, Hop siRNA
recapitulates the effect of GSNO to increase ΔF508 CFTR ex-
pression on the cell surface, representing a unique CF corrector.
Results
GSNO’s Effect on ΔF508 CFTR. We ﬁrst studied the relative ability
of low temperature (27 °C) (5, 22) and GSNO to up-regulate
ΔF508 CFTR expression in CFBE41o− cells using immunoblot
(IB) analysis. ΔF508 CFTR maturation was enhanced in rank
order: 27 °C < GSNO at 37 °C < GSNO at 27 °C (Fig. 1). We
also conﬁrmed the dose-dependent effect of GSNO to lead to
ΔF508 CFTR cell-surface expression (Fig. 2 A and B). Addi-
tionally, we showed that fully mature ΔF508 CFTR plasma
membrane expression increased in a dose-dependent fashion
after GSNO treatment (Fig. 2 C and D). We conﬁrmed the
identity of the core glycosylated (Figs. 1A and 2E, band B) and
fully glycosylated mature (Figs. 1A and 2A and E, band C) forms
of ΔF508 CFTR following 4 h of 10 μM GSNO (Fig. 2 A, C, and
E). Though core glycosylated CFTR was sensitive to endogly-
cosidase H (Endo H) digestion, the mature, fully glycosylated
CFTR (band C) was Endo H resistant, but sensitive to peptide
N-glycosidase F (PNGase F; Fig. 2E). We also investigated the
effects of GSNO on primary human pseudostratiﬁed columnar
epithelial cell (PCEC) cultures. Although GSNO (100 μM, every
6 h) failed to enhance forskolin-dependent Cl− transport relative
to vehicle control in Ussing chambers, a cell-permeable analog of
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GSNO, GSNO diethyl ester (GNODE, 60 μM) (18), increased
CFTR current (P = 0.02; Fig. 2F).
GSNO Decreases Hop Expression in Different Cell Lines. A CFTR
cochaperone, Hop, has a reduced cysteine in a potential
S-nitrosylation motif (24–26). We found that Hop is expressed in
CFBE41o− cells, A549 cells, and CFPAC-1 cells (Fig. 3A); 10 μM
GSNO (4 h) decreased Hop expression in all cells after 4 h (Fig.
3A); and GSNO decreased Hop expression in the cytosol in
a dose-dependent fashion (Fig. 3B). Exposure at 27 °C did not
recapitulate the effect of GSNO to decrease Hop expression (Fig.
3C). The GSNO-induced decrease in Hop expression was aug-
mented by cycloheximide (50 μg/mL 15 min before GSNO), but
not by 20 μg/mL actinomycin D (2 h before GSNO), suggesting
that (i) Hop protein is stable; (ii) the effect of GSNO is post-
transcriptional; and (iii) GSNO may lead to augmented Hop
degradation (Fig. 3D). When CFBE41o− cells were transfected
with 50 nM siRNA duplexes speciﬁc for Hop (48 h), Hop ex-
pression—but not that of Hsp70 or Hsp90—was inhibited (Fig.
3E). Further, GSNO at 10 μM for 4 h augmented the inhibition of
Hop expression by Hop siRNA (Fig. 3E). Taken together, these
data suggest that (i) Hop protein is normally stable in these cells
and (ii) GSNO accelerates Hop protein degradation.
Effect of GSNO on Regulation of CFTR Maturation by Hop. Knock-
down of endogenous Hop by siRNA in the absence of GSNO
increased levels of immature and mature forms of ΔF508 CFTR
(Fig. 3F). In the presence of GSNO (10 μM, 4 h), expression of
immature and mature forms of CFTR increased, but GSNO did
not augment the effect of Hop siRNA on ΔF508 CFTR matu-
ration (Fig. 3F), suggesting that the effect of GSNO to inhibit
Hop expression is important to the maturation effect of GSNO
on CFTR.
GSNO Alters the Association of Hop with CFTR in the Cytosol and ER
of CFBE41o− Cells. We hypothesized that the effect of GSNO to
decrease Hop expression would decrease Hop-CFTR association
during CFTR maturation. Cytosol, ER, and Golgi fractions were
isolated from CFBE41o− cells (27) with or without GSNO (10
μM, 6 h). We conﬁrmed the ER fraction contained calnexin but
not syntaxin 5, and the Golgi fraction contained syntaxin 5 but
not calnexin (Fig. 4A). From these fractions, we immunopreci-
pitated (IP’d) CFTR and IB’d for Hop after a pulse of GSNO.
Surprisingly, GSNO initially increased the association between
CFTR and Hop in the ER (at 2 h; Fig. 4B) but then, consistent
with inhibition of Hop expression (Figs. 3A and 4C), GSNO
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Fig. 1. Combination treatment (low temperature and GSNO) synergistically
up-regulates ΔF508 CFTR expression. CFBE41o− cells expressing ΔF508 CFTR
were grown at 37 °C to 70% conﬂuence, then incubated for an additional
48 h at 37 °C or 27 °C with GSNO (10 μM) present or absent (4 h). (A) Ex-
pression of the core glycosylated (band B) and mature, fully glycosylated
(band C) forms of ΔF508 CFTR was detected by immunoblotting using
mouse monoclonal anti-CFTR antibody (Chemicon). (B) Densitometric anal-
ysis revealed that the increases in the B and C bands were signiﬁcant for
both GSNO and 27 °C. Of note, combined treatment led to further full
maturation of band B. [*P < 0.001 by two-way ANOVA for each experiment
compared with no treatment/37 °C (C band) and both no treatment/GSNO
and GSNO/27 °C (B band)]. Data represent the average fold change for three
independent experiments.
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Fig. 2. GSNO cell-surface CFTR expression. (A and
B) Cell-surface expression. CFBE41o− cells were
treated with 5 or 10 μM GSNO (4 h). The glycosidic
moieties of cell-surface membrane proteins were
derivatized by exposing cells to sodium periodate
and biotinylation using biotin-LC hydrazide (30 min
at 20 °C). After IP and SDS/PAGE, biotinylated
CFTR (cell surface C band only) was detected with
streptavidin-conjugated HRP. The membrane was
reprobed with anti-α-tubulin. (ANOVA: *P < 0.001;
5 and 10 μM compared with control). Data repre-
sent the average fold change for three experiments.
(C and D) CFBE41o− cells were incubated with or
without 5 or 10 μM GSNO (4 h), and cell membranes
were isolated on a sucrose gradient before Western
blotting for cell-surface CFTR (C band only; ANOVA:
*P < 0.001, 5 and 10 μM compared with control).
Data represent the average of three experiments.
(E) Whole-cell extracts from CFBE41o− cells in-
cubated with or without 10 μM GSNO (4 h) were
Western blotted with anti-CFTR antibody A596 (50
μg protein/lane). Modiﬁcation of core glycosylated
(band B) and fully glycosylated mature (band C)
forms of CFTR was conﬁrmed by preincubation of
cell lysates with Endo H or PNGase F respectively (2
h, 37 °C). (F) Human CF primary pseudostratiﬁed
columnar epithelia at air-ﬂuid interface were ex-
posed to GSNO (100 μM every 6 h for 72 h to facil-
itate full-thickness penetration), membrane-
permeable GSNO diethyl ester (60 μM every 12 h for 48 h), or vehicle alone (for each) before analysis in Using chambers (42). Relative to vehicle, forskolin-
stimulated Cl− current was enhanced by GSNO diethyl ester (n = 4 donors, 2–3 wells each) but not by GSNO (n = 6 donors, three wells each). *P = 0.02.
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decreased CFTR-associated Hop in all fractions (Fig. 4B). Al-
though a GSNO pulse increases S-nitrosylation of proteins in the
ER, Golgi, and cytosol (18), CFTR-associated Hop S-nitro-
sylation was only observed on the cytosol and ER at baseline
(Fig. 4C), and no S-nitrosylated CFTR-associated Hop at all was
observed after a pulse of GSNO. Thus, S-nitrosylation of Hop
may prevent Hop association with CFTR, likely by augmenting
Hop degradation (see following). Figure 4D shows time-dependent
loss of CFTR-associated Hop (IP followed by IB) following treat-
ment with 10 μM GSNO in whole-cell extract. Additionally, we
used more sensitive LC-MS techniques to show that cytosolic Hop
was S-nitrosylated by 10 μM GSNO (2 h) in CFBE41o− cells in
which biotin-substituted proteins were isolated by streptavidin.
Figure 4E shows the relative intensity of one of the tryptic peptides
that was sequenced using tandem MS from the treated and un-
treated extracts. Table S1 lists the tryptic peptides from Hop and
their MS data. These ﬁndings conﬁrm that Hop is S-nitrosylated;
however, S-nitrosylation appears to target Hop for degradation.
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Fig. 3. GSNO, but not decreased temperature, decreases Hop expression to increase CFTR maturation. (A) CFPAC-1, CFBE41o−, and A549 cells incubated with
or without 10 μM GSNO (4 h) were Western blotted using monoclonal anti-Hop antibody (50 μg of protein per lane). The blot was reprobed with anti-
α-tubulin. (B) GSNO (4 h) decreased cytosolic Hop in CFBE41o− cells, as visualized by immunoﬂuorescence. (C) Western blot for cells were incubated for 48 h at
37 °C or 27 °C before exposure to GSNO; GSNO, but not 27 °C, decreased Hop expression. (D) IB of Hop from CFBE41o− cells treated for 4 h with GSNO with or
without pretreatment with actinomycin D or cycloheximide. (E) Hop Western blot from CFBE41o− cells treated with GSNO (10 μM, 4 h) after transfection with
Hop siRNA or scrambled sequence DNA; Hsp 70 and Hsp 90 were Western blotted as controls. (F) Western blot of Hop and CFTR from CFBE41o− cells
transfected with 50 nM of Hop siRNA (or control RNA) and analyzed after 48 h (50 μg protein per lane).
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Fig. 4. Hop S-nitrosylation decreases Hop expression and Hop-CFTR association. (A) Western blotting for calnexin and syntaxin 5 in the ER and Golgi fractions of
CFBE41o− cells. (B) IP with anti-CFTR followed by Western blotting with anti-Hop revealed CFTR-associated Hop exclusively in the cytosol at baseline. Exposure to
GSNO (10 μM) resulted in a translocation of CFTR-associated Hop to the ER at 2 h, with a subsequent loss of CFTR-associated Hop from all fractions thereafter. (C)
At baseline, some Hop associated with the CFTR was S-nitrosylated (IP for CFTR followed by biotin switch, streptavidin isolation, andWestern blot for Hop on each
fraction). After 2 h GSNO treatment (10 μM), no CFTR-associated S-nitrosylated Hop was present. (D) In a time-course analysis, GSNO (10 μM) decreased CFTR-
associated Hop (*P < 0.001 relative to baseline at 2 and 4 h, ANOVA). (E) Extracts from CFBE41o− cells treated with GSNO (10 μM, 2 h) underwent biotin switch
followed by avidin afﬁnity puriﬁcation, proteolysis, and LC-MS. The relative intensity of a representative peptide from S-nitrosylated Hop (LAYINPDLALEEK) from
treated and untreated cells is shown.
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Role of Hop Cysteine 403 in Hop Degradation. Hop has a cysteine
(C403) in a motif that can be associated with S-nitrosylation,
particularly under conditions of inﬂammation (26, 28). Over-
expression of C→S mutation of Hop Cys-403 resulted in (i)
protection from GSNO-induced Hop degradation and (ii) de-
creased Hop S-nitrosylation C403S relative to expression by
GSNO (Fig. 5A).
Hop S-Nitrosylation Promotes Its Proteasomal Degradation. The
proteasome inhibitor MG132 prevented depletion of total cel-
lular Hop after GSNO treatment (Fig. 5B). Further, S-nitro-
sylation (Fig. 5C) and ubiquitination (Fig. 5D) of Hop increased
after GSNO; these effects were increased by MG132.
Discussion
CF is caused by defective function of the cftr gene product. The
most common mutation, ΔF508 CFTR, results in the production
of an immature protein that is degraded, preventing correct lo-
calization to the plasma membrane (1, 2). However, if ΔF508
CFTR reaches the plasma membrane, it can function as a cAMP-
activated chloride channel (4, 7). Thus, there is interest in ﬁnding
corrector therapies to direct ΔF508 CFTR protein to the plasma
membrane. In vitro strategies have included low temperature
and chemical agents such as glycerol and 4-phenylbutyrate (22),
as well as GSNO and other S-nitrosylating agents (18). Strikingly,
previous studies (7, 14–19) and the current work suggest that low
micromolar GSNO concentrations increase maturation and cell-
surface expression of ΔF508 CFTR. Here, we show that GSNO
appears to act through a mechanism independent of—and ad-
ditive with—low temperature to increase ΔF508 CFTR matu-
ration and cell-surface expression. Inhibition of Hop expression
(and therefore of Hop association with CFTR) appears to be
required. Indeed, we report that Hop siRNA increases the ex-
pression and maturation of ΔF508 CFTR in human airway
epithelial cells.
GSNO itself has several features that could make it appealing
as a potential therapy for CF. (i) It is an endogenous compound
in the airways (8). (ii) Airway levels are low both in CF and
in asthma (29, 30). (iii) It has been used safely in human trials
(9, 31). (iv) It has CFTR-independent beneﬁcial effects that in-
clude relaxing airways smooth muscle, augmenting ventilation/
perfusion matching, increasing ciliary beat frequency, inhibiting
amiloride-sensitive Na+ transport, promoting inﬂammatory cell
apoptosis, and antimicrobial effects (8–13, 32). (v) It can in-
crease wild-type CFTR function (17). (vi) Last, it can increase
ΔF508 expression and maturation (7, 14–19), and the corrected
protein is functional in monolayer and primary nasal cells (4, 7).
Dose–response experiments in monolayer cell cultures suggest
that concentrations of 5–10 μM may be optimal (15, 16, 18)
(Fig. 2). These levels of GSNO appear to affect CFTR primarily
through posttranscriptional mechanisms (16). In the current
study, GSNO was ineffective in human airway pseudostratiﬁed
columnar epithelium. The culture system may not allow for
S-nitrosothiol uptake in all cell layers, preventing full thickness
effect. GSNO tissue effects require peptidases—such as γ glu-
tamyl transpeptidase—and active transport (10). These systems
may be variably expressed in cells at different depths of pseu-
dostratiﬁed epithelium, preventing a full-thickness effect on
overall Cl− transport. In support of this notion, a cell-permeable
GSNO analog, used at lower concentrations, modestly increased
functional ΔF508 CFTR expression in full-thickness cultures.
Thus, the effect of S-nitrosylating agents to increase ΔF508
CFTR maturation can be achieved in complex epithelial systems
if a cell membrane permeable ester is used.
Note that GNODE and GSNO release NO radical at roughly
the same rate (18), suggesting that the effect of GNODE on
ΔF508 CFTR function is independent of the conventional bi-
ology of NO radical. Indeed, biochemical data to date suggest
that NO+ transfer (transnitrosation) increases CFTR matura-
tion. (i) Several different S-nitrosylating agents have this effect,
and the activity of these agents is not related to either the rate at
which they form NO or their ability to serve as thiol donors (18)
(Fig. 2). (ii) The only common feature of all of these agents is
that they each can cause cysteine S-nitrosylation (18). (iii) The
effect is cGMP independent, inhibited by acivicin, and reversed
by DTT (15, 16, 18). Transnitrosation is important in several
signaling pathways relevant to health and disease in a variety of
cell and organ systems (10, 33).
Several proteins in the complex CFTR interactome (3) contain
reduced thiols that may be targets for transnitrosation (33).
Previously, we found that GSNO increases cysteine string pro-
tein (Csp) expression, and that this effect is relevant to the ef-
fect on CFTR trafﬁcking (18). We have also shown that GSNO
S-nitrosylates Hsc70, which may also be permissive for increased
CFTR maturation (18).
Here, we hypothesized that the effect of GSNO to increase
CFTR trafﬁcking to the cell surface in monolayer cultures would
be through an effect on Hop (also known as Stip 1). Hop is
a 60-kDa homodimer that links Hsp70 and Hsp90, central
components of the regulation of CFTR trafﬁcking, and it Co-IP’s
with CFTR (3). In addition, Hop is involved in cell-cycle regu-
lation and steroid receptor maturation (24, 34, 35), and it is
homologous to the CHIP complex, of importance to CFTR
degradation (36). Hop has a conserved cysteine (C403) (23, 24)
located in an S-nitrosylation motif believed to be relevant to
S-nitrosylation (26). We found that GSNO inhibited Hop ex-
pression in all cell lines. Suppression of Hop expression appears
central to the effect of GSNO on CFTR maturation: Hop siRNA
itself increased ΔF508 CFTR maturation.
Interestingly, Hop does not appear to be involved in the
mechanism by which decreased temperature increases ΔF508
CFTR maturation: (i) the effects of GSNO and hypothermia
were additive, and (ii) hypothermia did not inhibit Hop expres-
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Fig. 5. Hop degradation is prevented by C403S mutation and proteasomal
inhibition. (A) CFBE41o− cells untransfected or overexpressing either WT Hop
or C403S mutant Hop were treated for 2 h with 10 μM GSNO and Western
blotted for Hop (Upper) and actin (representative of two experiments). Ad-
ditionally, S-nitrosylated proteins from these samples underwent biotin sub-
stitution, followed by streptavidin isolation and Western blotting for Hop.
C403S mutation inhibited Hop S-nitrosylation in Hop-overexpressing cells.
(B) The proteasome inhibitorMG132 completely inhibited the ability of GSNO
(10 μM, 2 h) to decrease Hop expression. (C) MG132 also preserved S-nitro-
sylated Hop (C) and Hop ubiquitination (D) in CFBE41o− cells treated with
MG132 and/or GSNO. *P < 0.002; +P < 0.05.
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sion. This suggests that there is more than one pathway by which
ΔF508 CFTR can be induced to mature, and that the beneﬁcial
effects of these pathways may be additive. Temperature-sensitive
proteins other than Hop may be responsible.
The GSNO effect to decrease Hop expression was augmented
by cycloheximide pretreatment, but unaffected by actinomycin
D, suggesting both that Hop is normally stable and that there is
a posttranscriptional effect of GSNO on Hop expression. Con-
sistent with a previous report (28), we found that cytosolic Hop
is S-nitrosylated, but that GSNO treatment leads to loss of
total cellular Hop. Further, GSNO increases CFTR-associated
Hop in the ER transiently, then completely depletes all CFTR-
associated Hop and S-nitrosylated Hop. This would suggest that
rapid Hop degradation is favored by S-nitrosylation, preventing
its association with CFTR. Indeed, mutation of C403 both pre-
vented GSNO-induced Hop degradation in an overexpressing
system and decreased S-nitrosylation of overexpressed Hop. Note
that it is also possible that S-nitrosylation of a Hop-interacting
protein, such as Hsp90 (37), is also involved in signaling Hop de-
gradation, and cysteines other than C403 are S-nitrosylated (28).
However, C403 appears necessary to target Hop for degrada-
tion. Further, this S-nitrosylation-induced degradation is protea-
somal and appears to be signaled by ubiquitination: recovery of
Hop (Fig. 5B), S-nitrosylated Hop (Fig. 5C), and ubiquitinated
Hop (Fig. 5D) following GSNO treatment is augmented by
proteasomal inhibition.
The effects of GSNO to signal the degradation of Hop may
have relevance beyond its effect on CFTR trafﬁcking. Trans-
nitrosation reactions are increasingly recognized to be important
for cell signaling, and Hop interacts with and regulates the ex-
pression and function of a number of proteins that, themselves,
are functionally S-nitrosylated. These include Hsp90 itself, pro-
tein von Hippel Lindau, S100A class proteins, and others (37–
40). Hop is believed to have an array of important cellular
functions that could be affected by GSNO (23, 24), an important
consideration with regard to potential toxicities of S-nitrosothiol
therapies.
In summary, GSNO corrects ΔF508 CFTR trafﬁcking—per-
mitting cell-surface expression—by inhibiting Hop expression
and CFTR-Hop interaction. Indeed, Hop siRNA causes ΔF508
CFTR maturation, and it could be of interest to study adminis-
tration of Hop siRNA in animal models of CF. This effect is
additive with the Hop-independent effect of low temperature to
augment CFTR maturation, suggesting that different corrector
therapies could prove to be of synergistic beneﬁt for patients
with CF.
Materials and Methods
Cell Culture. CFBE 41o− cells were provided by Dieter Gruenart (San Francisco,
CA). CFPAC-1 and A549 cells were from ATCC. Cells were grown as previously
described (see details in SI Text).
Reagents. Reagents were from Bio-Rad and Sigma unless otherwise stated.
GSNO and GNODE were prepared as previously described (9, 18).
Immunoblotting. Immunoblotting was performed as previously described (15,
16, 18) (SI Text). Antibodies were as follows: mouse monoclonal anti-CFTR
R-domain-speciﬁc (R&D Systems); monoclonal anti-CFTR (Chemicon) or mono-
clonal antibody 596 (provided by J. Riordan); monoclonal anti-Hop (Stressgen);
monoclonal anti-Hsp70 (Abcam Inc.); monoclonal anti-Hsp90 and calnexin
(Abcam Inc.); and rabbit polyclonal anti-syntaxin 5 and anti-tubulin, as well as
rabbit polyclonal anti-ubiquitin (Stressgen). Modiﬁcation of core glycosylated
and fully glycosylated forms of CFTR was conﬁrmed by preincubation of cell
lysates with endoglycosidase H or peptide N-glycosidase F (New England
Biolabs).
Isolation of Cytosol, ER, and Golgi. Cells were rinsed twice with ice-cold PBS,
trypsinized, and pelleted by centrifugation (5,000 rpm, 10 min). The pellet
was washed (×2) in ice-cold PBS and then suspended in 50 mM Tris·HCl (pH
8.0) with 0.5 M sucrose. After undergoing centrifugation (5,000 rpm, 10 min
at 4 °C), the supernatant was transferred to ultracentrifuge tubes. The cy-
tosol was clariﬁed (48,000 rpm, 60 min at 4 °C). A total of 2.3 M sucrose stock
was added to a concentration of 1.25 M sucrose. A sucrose density step
gradient was performed in an ultracentrifuge tube using a paired gradient
(by weight) with a balance tube. Organelles were separated by density
gradient (48,000 rpm, 2 h at 4 °C). Off-white bands of Golgi membrane and
endoplasmic reticulum membrane were harvested (4 °C) with a Pasteur pi-
pette (18, 27).
Immunoprecipitation. Cytosolic, ER, and Golgi fractions were transferred to
chilled Eppendorf tubes. Ten microliters of primary CFTR antibody (anti-CFTR
clone L12B4 and anti-CFTR clone M3A7, mouse monoclonal antibodies;
Upstate) was added to each fraction and incubated overnight at 4 °C with
gentle shaking. Supernatant antibody mixtures were treated with 70 μL of
Protein A (Boehringer Mannheim) and incubated for another 4 h. Then,
samples underwent centrifugation (1 min), and proteins not bound to the
beads were removed by washing beads twice with RIPA buffer. Proteins
were then eluted from beads by incubation with 100 μL sample buffer at
room temperature with continuous mixing for 1 h. Samples were divided
into two aliquots: one for S-nitrosothiol assay and the other for IB.
Immunoﬂuorescence. CFBE41o− cells grown on glass coverslips to conﬂuence
were treated, washed (×2) with 5 mL of complete Dulbecco’s PBS (OW-PBS),
ﬁxed with 3.7% paraformaldehyde (5 min), washed two times with 1× OW-
PBS, permeabilized by 0.1% Triton X-100 in OW-PBS (vol/vol, 10 min),
washed two times with 1% PBS then with 1% BSA in OW-PBS, incubated in
1% BSA in OW-PBS for 45 min at RT, then incubated with anti-Hop antibody
(1:100, 4 °C, overnight; Stressgen). Cells were then washed (×2 for 5 min)
with 0.1% BSA in PBS, incubated with secondary antibody for 30 min at
room temperature (1:500, Alexa Fluor 488; Invitrogen), mounted, and visu-
alized using confocal microscopy (customized Zeiss equipment).
Cell-Surface Biotinylation. CFBE41o− cells were treated for 4 h with or with-
out GSNO. The cells were washed (×3) with ice-cold PBS (pH 7.4) containing
0.1 mM CaCl2 and 1 mM MgCl2 (PBSCM) and then treated in the dark with
PBSCM buffer containing 10 mM sodium periodate for 30 min at 20 °C . The
cells were washed (×3) with PBSCM and biotinylated by treating with sodium
acetate buffer [100 mM sodium acetate buffer (pH 5.5), 0.1 mM CaCl2 ,and 1
mMMgCl2] containing 2 mM biotin-LC hydrazide (Pierce) for 30 min at 20 °C
in the dark. The cells were then washed (×3) with sodium acetate buffer and
solubilized with lysis buffer containing Triton X-100 and protease inhibitors
(26). CFTR was IP’d as described and subjected to SDS/PAGE on 6% gels (27);
biotinylated CFTR was detected with streptavidin-conjugated HRP.
Cell Membrane Preparation. CFBE41o− cells stably expressing ΔF508 CFTR
were grown to conﬂuence, then were treated for 4 h in the absence or
presence of 5 and 10 μM GSNO. The cells were harvested in ice-cold PBS and
homogenized with a Dounce homogenizer in buffer containing 0.5 M su-
crose, 2 mM EDTA, 0.1 mM PMSF, 10 mM Hepes, and protease inhibitors (pH
7.4). Nuclei, mitochondria, and cell debris were pelleted (15 min, 10,000
rpm). The supernatant was centrifuged at 48,000 rpm for 2 h. The resulting
supernatant was recovered as cytosol, and the membrane as a pellet. Total
protein was assayed on each fraction (Bradford).
Ussing Chamber Experiments. Under the auspices of the University of North
Carolina at Chapel Hill Institutional Review Board-approved protocol, pri-
mary human bronchial epithelial cells were obtained from lungs explanted
during transplantation. Passage 2 cells from six different ΔF508 CFTR ho-
mozygous individuals were cultured at an air-liquid interface for study in
Ussing chambers as described in detail previously (42). CFTR function was
assayed as forskolin-stimulated Cl− current in PCECs that had been treated
with amiloride; 10 μM CFTRinh-172 (Sigma) was added after forskolin. ΔF508
CFTR homozygous PCECs were exposed (blind) to GSNO (100 μM every 6 h ×
72 h) or (GNODE 60 μM every 12 h × 48 h) before assay.
S-Nitrosothiol Assays. S-nitrosylated proteins were assayed by the biotin sub-
stitution as previously described (28). CFTR IP (noted previously) was carried out
on each fraction at each time, followed by biotin substitution, streptavidin
isolation, and IB for Hop. Additionally, biotin-substituted S-nitrosylated pro-
teins were assayed by LC-MS, as follows.
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Liquid Chromatography/Mass Spectrometry Assay for S-Nitrosylated Proteins.
Biotin substitution proteins were analyzed by LC-MS as previously described
(43) with modiﬁcations as noted in SI Text.
Small Interfering RNA Knockdown of Hop. To conﬁrm the role of Hop in ΔF508
CFTR maturation, siRNA sequences were synthesized and then identiﬁed
(using matrix-assisted laser desorption ionization/time-of-ﬂight spectro-
metric analysis; QIAGEN Inc.). Hop siRNA duplexes were >90% pure as
measured by HPLC analysis with sense r(CAA UGA UGG UUG AGU GAA)dTdT
and antisense r(UUU CAC UCA ACC AUC AUU G)dTdA. Scrambled Hop siRNA
was used as a control. For transfection, CFBE41o− cells were transfected with
50 nM of Hop construct using Lipofectamine 2000 (Invitrogen). After 48 h of
transfection, with or without preincubation with GSNO (10 μM, 4 h), cells
were rinsed three times with PBS and lysed directly on plates using lysis
buffer containing protease inhibitors.
Site-Directed Mutagenesis. The C403S mutant was made using the Quik-
Change Multi Site-Directed Mutagenesis Kit from Stratagene according to
the manufacturer’s instructions. Primers were as follows: Cys403-Ser-5′
CGAGCTGCCTCCTACACC-3′ and Cys403-Ser-3′ GGTGTAGGAGGCAGCTCG-5′.
Primers (100 ng) were incubated with DNA template (100 ng) in reaction
buffer (25 μL), dNTP mix (1 μL), and Quick change multienzyme blend (1 μL)
for 95 °C × 2 min (one cycle), then for 65 °C × 8 min (25 cycles). After in-
cubation, the mixture was digested with Dpn 1 enzyme for 1 h, followed by
transformation in XL10-Gold Ultracompetent Cells (Stratagene). Positive
colonies (blue) were selected for transfection in LB-agar plates. DNA was
puriﬁed using QIAprep SpinMiniprep Kit (QIAGEN Inc.). For transfection, 1 × 106
cells per well were plated on six-well plates and transfected with 50 nM of
Hop construct using Lipofectamine 2000 (Invitrogen) as recommended by
the manufacturer. After 48 h of transfection, and with or without prein-
cubation with GSNO (10 μM, 4 h), cells were studied by IB.
Statistical Analyses. We conducted two-way ANOVAs for each experiment.
In each model, we included the main effects of treatment and band,
and their interaction. The statistical analyses were carried out in SAS 9.1
(SAS Institute Inc.). Multiple comparisons were adjusted by Dunnett’s
method.
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